MYHIBBIN J Code: J7514

Drug & Product Overview

HCPCS Descriptor Mycophenolate mofetil (myhibbin), oral suspension, 100 mg

HCPCS Added Date January 1, 2025

Manufacturer Azurity Pharmaceuticals Inc

Route of Administration Oral

Generic Status Single-Source; Branded

Dosage Form Suspension

About MYHIBBIN

Myhibbin is a medication aligned to the HCPCS J Code: J7514 for billing, pricing, and reimbursement purposes in the United States. Classified under Immunosuppressant, it is administered via the oral route and manufactured by Azurity Pharmaceuticals Inc.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
24338-0018-01	Myhibbin	Azurity Pharmaceuticals, Inc.	350	35000 MG / 175 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

MYHIBBIN Pricing & Reimbursement

J7514 Private Payer Reimbursement

$2.18 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Mycophenolate Mofetil 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J7514	Azurity Pharmaceuticals Inc	Mycophenolate Mofetil	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
J7519	Generic Code (Multiple Manufacturers)	Mycophenolate Mofetil	Injection, mycophenolate mofetil, 10 mg
J7528	Generic Code (Multiple Manufacturers)	Mycophenolate Mofetil	Mycophenolate mofetil, for suspension, oral, 100 mg
J7530	Azurity Pharmaceuticals Inc	Mycophenolate Mofetil	Mycophenolate mofetil (myhibbin), oral suspension, 5 mg

MYHIBBIN Medically Unlikely Edits (MUE)

The most billing units of J7514 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 100 mg.

Practitioner Office & Hospital Outpatient

30 units / day

= 3,000 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

MYHIBBIN Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Heart transplant rejection prophylaxis Kidney transplant rejection prophylaxis Liver transplant rejection prophylaxis

Drug Class

Antimetabolite Immunosuppressant [EPC]

Frequently Asked Questions

Is there an available MYHIBBIN billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for MYHIBBIN.

What are the available MYHIBBIN patient assistance programs?

MYHIBBIN patient assistance information can be found through Azurity Pharmaceuticals Inc. Visit Here →

Where can I find MYHIBBIN prescribing information?

MYHIBBIN prescribing information can be found at the link below. Visit Here →

Where can I find MYHIBBIN side effect information?

MYHIBBIN side effect information can be found through MedlinePlus at the link below.

Does billing MYHIBBIN require JZ/JW wastage modifiers?

CMS does not include MYHIBBIN (J7514) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J7514. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.